远大医药二零二三年中期报告

212596484 (MRA)MRAMRA STC3141II ccRCCRDCTLX250–CDxI STC3141Ib Novasight Hybrid System GPN00833(APP13007)FDANDA Ryaltris®(GSP301)III GEP-NETsRDCITM–11I 3,750BlackSwanBlackSwan87.5%LavaTMKonaTM[90Y][90Y]LavaTMKonaTM GPN00136 (BRM421)II GPN00833(APP13007)III APP13007IIIII RDCTLX101I APADI HeartLight X3 STC3141Ib Jext® ®®II®®IIIII2022 AF(Atrial Fibrillation)APERTO® OTWARDSBlackSwanBlackSwan Vascular, Inc.ccRCCCOVID-19FDA(United States Food andDrug Administration)GEP-NETsGrand Pharma SphereGrand Pharma Sphere Pte LimitedICSITMITM Isotope Technologies Munich SELABA2LAMALEGFLOW® OTWMRMRAmRNA NovasightNOVASIGHT Hybrid SystemNMPAPCIRDCRESTORE DEB®SARS-CoV–2SirtexSirtex Medical Pty Ltd.TelixTelix Pharmaceuticals Limited 412610221 —TLX250-CDxI—TLX101I—ITM-11I—LavaTMFoodand Drug AdministrationFDA—KonaTMFDAPremarketApprovalPMA —HeartLight X3—HeartLight X3—NOVASIGHT Hybrid SystemNovasight—® —® —®®®®2022—Ryaltris®III—STC3141Ib—STC3141II—APADI —BRM421II—GPN00833III—CBT-001III —Jext® 10(15ml) 2REACH 2 BlackSwan Vascular, Inc.BlackSwan87.5%BlackSwan2018Sirtex Medical Pty Ltd.Sirtex 201820222022TOP10019 mRNA 30OTC++ 2021202020192017 —• 2022201820 GPN00153CBT-001 IICBT-001IIIIII GPN00833 IIIIIGPN00833FDA(NDA)III GPN00136 (BRM421) BRM421IIIIIII GPN00884 10®®®® ARDSRyaltris®IIISTC3141ARDSCOVID-19COVID-19ARDSAPADI ®®®® (2021)(2021)(2020)—(2015) ®®II®®IIIII ®®2(LABA)(ICS)(1)ICSLABA(LAMA)ICS-LABA CS-LABALAMA®®(2)(3)®IIIARGON®®2443%®®ICSLABA12®®III®®26%22%19%2022 — ARDS Ryaltris® Ryaltris®12III STC3141 STC3141NatureCommunicationsARDSCOVID-19COVID-19ARDSIbARDSIb COVID-19IIaII APAD APADSTC3141I GPN00085 GPN00085—(HN) 301416MRA20Jext® Q10 (2021)(2021)(2021)2021(2021)(2018)(2018)(2017)2016 ESC2 3 2014/2017/2020(2016)120172018/20202020 Q10 Q10302023(2021)(2021)202020 MRAmineralocorticoid receptorMRMR2018(2022)MRAMRAMRAMRMRMRA 20202020(2020) (2022)2018202020212 Jext®GPN00816 GPN008162110 mRNAmRNAmRNALNPHPVmRNAA002TriMix mRNA 40040%SirtexTelix Pharmaceutical LimitedTelixITM Isotope Technologies Munich SEITMRDC1368Ga177Lu131I90Y89Zr99mTc68—RDC ®[90Y]RDC25®[90Y] ®[90Y] ®[90Y]SIRT5015(BCLC)(NCCN)(ESMO)(European Association for theStudy of the Liver, EASL)(National Institute for Health and Care Excellence, NICE) CSCO202220182018 ®[90Y] ®[90Y]®6017407®103®50%3070% ®FDA70400®206® ®[90Y]1133 RDC ®[90Y] ®[90Y] GPN00289 GPN00289 LavaTM LavaTMLavaTM320LavaTM[90Y] KonaTM KonaTM[90Y][90Y]KonaTMFDAPremarketApprovalPMA AuroLase® AuroLase®AuroLase®AuroLase® RDC 9 TLX591TLX591CDx TLX599CDx TLX591(PSMA)RDCTLX591-CDxTLX599-CDxTLX591TLX591-CDxTLX591-CDxIII ccRCCTLX250TLX250CDx TLX250TLX250-CDxTLX250-CDxFDA(CT)(MRI)ccRCCTLX250-CDx(PET)ccRCC86%87%FDA70%93%T1accRCC4cmTLX250-CDx85%89%TLX250-CDxccRCCccRCCTLX250-CDx(TNBC)(NMIBC)TLX250-CDxIITLX250II GEP-NETsITM-11TOCscan® ITM-11TOCscan®ITM-11FDA(EMA)IIIITOCscan® TLX101 TLX101—RDCL1(LAT-1)FDAIIITLX101I ITM-41 ITM-41177LuRDCI 167NovasightHeartLight X3 +2006060% RESTORE DEB®APERTO®OTWSAFEPAXNovasightPCIOTWOver The Wire®®®® RESTORE DEB® RESTORE DEB®JACC (Journal of the American College ofCardiology) Cardiovascular Interventions APERTO®OTW APERTO®OTWAPERTO®OTWAmerican Journal of Kidney Diseases Novasight Novasight(IVUS)(OCT)FDA ® ®OTW® ® ®®® ® ®35 ® ®360 LEGFLOW®OTW LEGFLOW®OTWSAFEPAX IVL CADIAL PAD IVL CADIAL PAD LONG LONG624 aXess aXess(ESRD)(AVG)aXessAPERTO®OTW Saturn Saturn HeartLight X3 HeartLight X3atrial fibrillationAFFDAAFHeartLight X3AFHeartLight X3 CoRISMA CoRISMA 1004020— 20 110(ELI) EU GMPREACHKFDAMAPAISOFSSC22000GRASHALALKOSHER 502470%FDA 14050%500 5,989,490,0005,212,580,00014.9%22.6%1,029,350,000Telix229,150,000323,390,0001,123,600,0003.1%10.0%64.6%62.5% 1,637,680,000695,890,0001,373,120,000550,760,00019.3%26.4% 113,230,00063,210,000 4.97 3,551,420,000554,040,000984,560,000 2,886,290,000398,170,000161,590,000166,330,000 5% AGrand Pharma Sphere57.98%Grand Pharma Sphere57,200,00041,000,0009,800,000 B55%54,800,000110,300,000279,400,000 C5% 1)Grand Pharma Sphere 2) 3) 13348 mRNAmRNA RDC— 70040060% (15ml)(15ml) (15ml)2719 727523159.6%4660371STC31414PCT37 3,7003,30022,000OTC1,000251401,40022050®[90Y] 8330 + •BlackSwan 3,750BlackSwanBlackSwan87.5%LavaTMKonaTM[90Y][90Y]LavaTMKonaTM 39,015,000(1)(2)27,090,0007,270,000 5,000,00010,000,00011,200,00010,000,000 1.4920193%1.36 3.4%15.6% OncoSec Medical IncorporatedOncoSecOncoSec OncoSec59,650,0002.9%OncoSec 263,370,000266,540,00047,257,5001.3%30,300,00022,430,5000.85%0.63% 5%177,478,5571%35,495,711 10,12410,172 XVXV78352 35278 XV23336 1.Outwit1,671,671,149Outwit99.85%0.15%1,671,671,149 2.70%255,142,14830,897,005286,039,153 3.41,520,0001,999,230,302 5.CNCB (Hong Kong) Investment Limited208,750,000 China CITIC Bank Corporation LimitedCNCB (Hong Kong) Investment Limited99.05%China CITIC BankCorporation LimitedCITIC Limited65.97%CITIC LimitedCITIC Group Corporation58.13%208,750,000 6.GL Tra